OncoMed Pharmaceuticals Appoints Perry Karsen to Board of Directors
January 06, 2016 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc., (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Achieves $72.5 Million in Milestone Payments From Celgene; Announces Year-End Cash Balance
January 05, 2016 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
$70 Million Safety and $2.5 Million Clinical Candidate Designation Milestones Achieved Enters 2016 with $227 Million in Pro-Forma Cash REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) --...
OncoMed Presents Vantictumab Biomarker Data at the San Antonio Breast Cancer Symposium (SABCS)
December 11, 2015 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented new data related to the development of a novel predictive biomarker for vantictumab...
OncoMed Presents Data From Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November 09, 2015 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented clinical and preclinical data related to three of its clinical-stage programs at the...
OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
November 07, 2015 12:45 ET
|
OncoMed Pharmaceuticals, Inc.
NATIONAL HARBOR, Md. and REDWOOD CITY, Calif., Nov. 07, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and...
OncoMed Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 05, 2015 07:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology...
OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial of Anti-Notch1 (OMP-52M51) in Oral Plenary Session at the 26th EORTC-NCI-AACR Symposium
November 19, 2014 07:50 ET
|
OncoMed Pharmaceuticals, Inc.
BARCELONA, Spain and REDWOOD CITY, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem...
OncoMed to Present Data From Three Clinical Studies at the 2014 ASCO Annual Meeting
May 14, 2014 17:02 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
December 03, 2013 07:30 ET
|
OncoMed Pharmaceuticals, Inc.
Celgene Invests in OncoMed's Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and...